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Description
Historically, Superficial Femoral Artery (SFA) lesions have been 
successfully treated using open surgical approach. A matter of debate 
has been about the best graft to be used: veins seem good options for 
below the knee district, synthetic graft should be used for above the 
knee region. However poor reported primary and assisted patency rates 
justify the need for a therapy with good procedural success, limited 
invasiveness and improved long-term outcomes. An increasing number 
of patients actually undergo endovascular treatment as a first line 
therapy for lesions in the femoro-popliteal district, for both intermittent 
claudication and critical limb ischemia. TASC II guidelines in fact 
showed that in short lesion (type A and B) endovascular treatment 
performs better than open surgery [1]. Abstention to surgery also could 
be an option in selected cases, with lifestyle education and exercise 
training program associated to medical treatment for claudicant 
patients. According to TASC guidelines [1], only Cilostazol and 
Pentoxifylline have been approved by FDA to improve walking distance 
in patients with intermittent claudication. Other proposed medical 
therapies, such as propionyl-L-carnitine, are still under investigation.
In patients with clinical limb ischemia, parenteral administration of 
PGE-1 or iloprost for 7 to 28 days may be considered to reduce ischemic 
pain and facilitate ulcer healing, but its efficacy is likely to be limited to 
a small percentage of patients.
Best interventional treatment for SFA lesions however is still the 
subject of some controversies. In particular, the great topic is about the 
routinely use of stent versus simple PTA in this district. It appears quite 
impossible to define which treatment is the best as data emerging from 
literature lacks of consensus. Making a comparison among different 
studies seems to be difficult, so the conclusions must be interpreted in 
the context of the individual studies [2]. Differences could be detected 
regarding selection criteria of patients involved (TASC A and B versus 
TASC C and D, claudication versus critical limb ischemia). Peripheral 
flow and runoff are essential for good patency of treated districts 
according to some authors, while they are not in some other studies 
[3]. Last, different endpoints are considered for evaluation of outcomes, 
for example limb salvage, primary patency and clinical improvement or 
ABI improvement. For these reasons, primary and secondary patency 
rates as well as restenosis rates among these studies are not easily 
comparable.
Some help may come from conclusions reported by a recent 
Cochrane review: stenting placement is associated with a higher 
immediate success rate, but not with a statistically significant 
improvement of primary patency rate at middle/long term follow-up 
[4]. 
Moreover, eventual occlusion of the stent leads almost inevitably to 
bypass surgery, on the otherside SFA reocclusion after simple PTA can 
be addressed with a redo PTA.
So routinely stenting has to be discouraged and reserved selectively 
in cases of important vessel recoiling, recanalization of total occlusion, 
dissection and hard calcification. 
The use of covered stent has also been advocated for the treatment of 
SFA lesion. Lammer and Coll [5] performed a prospective randomized 
multi-center study comparing 141 patients with symptomatic peripheral 
arterial disease who were assigned to treatment with heparin-bonded, 
covered stents (Viabahn 72 patients) or bare medical stents (BMS, 69 
patients) for complex femoro-popliteal lesions. They demonstrated 
significant clinical and patency benefits for heparin-bonded covered 
stents compared with BMS in lesions ≥ 20 cm and for all lesions in 
the treating-per-protocol analysis, however in the intention-to-treat 
analysis for all lesions the difference was not significant. Moreover, the 
main concern about the use of stent-graft is the coverage of important 
collateral vessels arising from the SFA, which can lead to an irreversible 
ischemia in case of graft failure.
Non-inferiority of endovascular techniques versus traditional 
surgery in short lesions (TASC A and B) is an irrefutable statement 
arising from literature, however new technologies are needed to improve 
long term patency rates. For these reasons, in last year’s new devices and 
innovative technologies have evolved, making endovascular treatment 
of TASC II type C and D lesion (long lesion) feasible as well. Devices 
already in use for coronaric district, such as Drug Eluting Stents (DES), 
Drug Eluting Balloons (DEB) and Directional Atherectomy (DA) are 
now used for peripheral vessels. 
According to early studies DES and DEB in the peripheral district 
don’t show similar results as for coronaric district. However, Zeller 
and Coll [6] in a recent retrospective dual center study evaluated the 
performance of DEB and DES in long (≥ 10 cm ) femoropopliteal 
lesions in 228 patients. They concluded that DEB and DES performed 
equally well in the endovascular treatment of these lesions and better 
than traditional endovascular treatment.
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DA is associated to early and middle term outcomes which 
are similar to those of percutaneous angioplasty alone. DA offers 
some possible advantages, such as plaque excision and gradual and 
progressive increasing of vessel diameter. It may be an alternative tool 
to avoid stent placement.
The device gets on along the vessel; at the distal end of the catheter 
a rotating inner blade provides to plaque excision and a reservoir 
captures debris from the plaque. Early studies reported a procedural 
success in 98% of cases, with a complication rate of 5% and a patency 
rate of 80% at 6 months [7].
In our Institution, DA using SilverHawk and TurboHawk has been 
used since 2011 on 46 SFA lesions in 34 patients who were mainly 
affected by critical limb ischemia (76.5%). Primary patency at 3 years 
was 44% with a 97% rate of limb salvage. 
Siderbars and Coll [8] evaluated distal embolization following 
DA, which could compromise a good runoff. To avoid peripheral 
embolization, the use of Embolic Protection Devices (EPDs) such 
as filter has been proposed, in particular the longer the lesion to be 
treated, the more is the needing to use EPDs. However symptomatic 
embolization is less frequent than asymptomatic embolization, which 
usually can be revealed by Doppler Ultrasound. Authors conclude that 
asymptomatic embolizations are more frequent than symptomatic; 
however they don’t imply an impoverishment of peripheral runoff. 
Promising clinical and technical results in recently published 
prospective studies reporting on DA-assisted angioplasty in femoro-
popliteal lesions have been compared to results of Subintimal 
Angioplasty (SIA). According to Indes and Coll [9], SIA appeared 
superior to atherectomy for the treatment of lower extremity occlusive 
disease. In this study, however, TASC C and D lesion are treated, but we 
know that DA is not appropriated for this kind of lesions. 
Again, the conclusions must be interpreted in the context of the 
individual studies and randomized prospective controlled trials are 
needed, to help unravel this maze of vines.
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